Cancer Medicine Prices Cut in India from 9 November 2026: Check New MRP, Affected Drugs and Patient Rights

Cancer Medicine Prices Cut in India from 9 November 2026: Check New MRP, Affected Drugs and Patient Rights

MASA World featured image about India's revised prices for selected cancer medicines, NPPA price regulation and patient affordability.
India’s revised prices for selected anti-cancer medicines – MASA World.

Last updated: 10 November 2026

India’s revised maximum retail prices (MRPs) for selected anti-cancer medicines took effect on 9 November 2026. The National Pharmaceutical Pricing Authority (NPPA) introduced the changes under Trade Margin Rationalisation (TMR), covering 137 identified non-scheduled anti-cancer drugs. This is a price-regulation measure—not the launch of a new cancer drug, and not a blanket discount on every cancer medicine.

The Department of Pharmaceuticals reported revised MRPs for 1,364 formulations in its 9 November announcement. It estimated annual consumer savings at ₹3,540.38 crore. The government also reported that 679 brands recorded price reductions above 50%, with the highest reported reduction reaching 96.45%. These figures describe the reported programme-wide impact. They do not mean every cancer medicine has become cheaper.

Patients and caregivers should verify the exact medicine, brand, strength, dosage form and pack size against the latest NPPA list before paying. The figures in this article are government-reported programme totals; an individual patient’s saving depends on the exact product prescribed and purchased. This guide explains what changed, how to verify a price and how to report suspected overcharging.

Key Takeaways

  • Revised MRPs for the identified anti-cancer medicines took effect on 9 November 2026.
  • The NPPA intervention covers 137 identified non-scheduled anti-cancer drugs; it is not a universal discount on all cancer medicines.
  • The 30% figure is a trade-margin cap, not a guaranteed 30% reduction in every medicine’s MRP.
  • Check the exact brand, strength, dosage form and pack size against the latest NPPA price list before purchase.
  • Keep the bill and report suspected overcharging through official NPPA grievance channels.
  • Never change or stop a prescribed cancer treatment without consulting the treating oncologist.

1. Executive Summary

The NPPA introduced revised MRPs for selected anti-cancer medicines through Trade Margin Rationalisation. The policy targets excessive trade margins across the supply chain. The government announced the measure on 17 October 2026. The revised prices became effective on 9 November 2026.

The 9 November government update reports revised MRPs for 1,364 formulations across 121 drugs, based on submissions from 85 pharmaceutical companies. It estimates annual consumer savings of ₹3,540.38 crore and reports a highest brand-level reduction of 96.45%. Read the government announcement.

This is not a universal discount on all cancer medicines. It applies to selected drugs and formulations. A patient’s actual savings depend on the exact prescribed product and its revised MRP.

2. Important Facts at a Glance

DetailOfficial information
PolicyTrade Margin Rationalisation
AuthorityNational Pharmaceutical Pricing Authority
Responsible departmentDepartment of Pharmaceuticals
Identified medicines137 non-scheduled anti-cancer drugs
Policy announcement17 October 2026
Revised prices effective9 November 2026
Reported formulations1,364
Companies reporting revised prices85
Brands with reductions above 50%679
Highest reported reduction96.45%
Estimated annual consumer savings₹3,540.38 crore
Price verificationNPPA website and Pharma Sahi Daam
Complaint channelPharma Jan Samadhan
NPPA helpline1800-11-1255 (working days, 10 AM–6 PM)

3. What Changed on 9 November 2026?

The NPPA introduced revised prices under its Trade Margin Rationalisation policy for 137 identified non-scheduled anti-cancer drugs. Under the intervention, the maximum permissible trade margin is capped at 30% for the covered medicines. This is a cap on trade margins in the supply chain—not a promise that every medicine’s MRP will fall by 30%.

The government says the policy includes certain patented anti-cancer medicines. It aims to reduce excessive price differences across the medicine supply chain. The change is intended to make selected treatments more affordable for patients and families.

4. Understanding the NPPA Price-Control Decision

The National Pharmaceutical Pricing Authority (NPPA) is the Government of India’s specialised medicine-price regulator. It functions under the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. Its work includes implementing price-control orders, monitoring prices of scheduled and non-scheduled medicines, reviewing compliance and taking action where companies or sellers violate applicable price rules.

The October 2026 intervention followed recommendations from an Expert Committee constituted by the Directorate General of Health Services (DGHS) on 17 October 2026. The NPPA used the public-interest power available under Paragraph 19 of the Drugs (Prices Control) Order (DPCO), 2013 to bring 137 identified non-scheduled anti-cancer medicines under trade-margin rationalisation. The measure is therefore a regulatory price intervention, not a new drug approval or a clinical treatment guideline.

Scheduled and non-scheduled medicines: why the distinction matters

Under the DPCO framework, scheduled medicines are listed in the First Schedule and are subject to government-fixed ceiling prices. Non-scheduled medicines are not in that schedule; their prices are monitored under the applicable provisions. The October 2026 order specifically targets 137 identified non-scheduled anti-cancer medicines, including patented medicines. It does not replace the separate ceiling-price rules that already apply to scheduled medicines.

The policy also builds on an earlier trade-margin rationalisation intervention introduced in 2019 for 42 non-scheduled anti-cancer medicines. The 2026 measure expands the approach to a wider identified group. The official NPPA and Department of Pharmaceuticals documents should be treated as the controlling references if a medicine’s coverage or price is disputed.

5. What Is Trade Margin Rationalisation?

Trade margin is the difference between the price a manufacturer charges a stockist or distributor and the maximum retail price (MRP) that a patient may be charged, excluding GST. Between the manufacturer and the patient, a medicine may pass through stockists, distributors, retailers, pharmacies and hospital pharmacies. The margin cap is designed to limit the mark-up within this supply chain.

For the identified medicines, the order caps the trade margin at 30% of the MRP. The calculation uses the average price-to-stockist or distributor price from March 2026 as its reference point. GST is added separately as applicable. The exact notified MRP for each formulation—not a patient’s own calculation—must be used at the point of sale.

Why does this matter? A medicine can have a substantial gap between its procurement or distributor price and the MRP. When that gap is large, the patient bears the higher retail cost. A margin cap seeks to reduce excessive mark-ups while retaining a regulated channel for distribution. It does not mean the manufacturer price, hospital treatment bill or total cancer-care cost will all fall by the same percentage.

The 30% figure is a trade-margin cap. It is not a guaranteed 30% discount for every patient, nor does it mean every covered medicine will have the same reduction. The actual MRP change depends on the medicine’s earlier price structure and the applicable calculation. Patients should use the official revised MRP rather than calculate a price themselves.

6. Which Anti-Cancer Medicines Are Covered?

The notified group contains 137 non-scheduled anti-cancer drug substances or combinations. The government’s published list includes medicines used in different treatment settings, such as Bevacizumab, Denosumab, Pegfilgrastim, Pembrolizumab, Nivolumab, Osimertinib, Olaparib, Pemetrexed, Pertuzumab, Abemaciclib and many others. This is an illustrative selection, not a complete list and not a recommendation to use any of these medicines.

The official NPPA page provides date-wise revised MRP documents. The 9 November 2026 document is the latest list identified for this article’s research cut-off. Open the document and search by the generic name or brand, then match the strength, dosage form, pack size and manufacturer. Do not assume that every brand, strength or pack of a drug has the same price.

Official coverage list: PIB backgrounder – list of 137 anti-cancer medicines and NPPA date-wise revised-price documents.

These medicines have different clinical uses. Their use depends on the formulation and the patient’s clinical circumstances. Patients should follow their treating doctor’s instructions. They should never change a medicine based only on a price announcement.

The policy does not cover every brand or every cancer medicine. Different strengths and dosage forms can have different MRPs. Pack size and manufacturer details also matter. Always match the exact product before comparing prices.

7. How Much Can Patients Save?

The Department of Pharmaceuticals’ 9 November update reported revised MRPs for 1,364 formulations, covering 121 drugs, based on submissions from 85 companies. It reported that 679 brands had reductions above 50%, with the highest reported reduction at 96.45%, and estimated annual consumer savings of ₹3,540.38 crore. These are programme-wide reported figures—not a guaranteed discount, refund or benefit amount for an individual patient.

The 7 November PIB update published selected brand-level examples. The table below reproduces a selection of those government-reported figures to illustrate why the exact brand and formulation matter. It is not a full price list; use the latest NPPA document for a purchase decision.

Medicine and brandEarlier MRPRevised MRP
Bevacizumab 100 mg injection – Bryxta₹25,995.00₹3,318.00
Bevacizumab 100 mg injection – BevaciRel₹24,079.00₹3,985.00
Bevacizumab 100 mg injection – CIZUMAB₹15,658.00₹3,103.00
Bevacizumab 100 mg injection – Versavo₹7,686.00₹3,504.23
Denosumab 60 mg injection – DenOsteoRel₹24,955.00₹6,240.00
Pemetrexed 500 mg vial – ReliTrexed₹9,977.00₹1,113.00
Pemetrexed 500 mg vial – PEMETOMED₹5,062.00₹940.00
Pemetrexed 500 mg vial – ADPEM 500₹5,499.00₹1,035.05
Pemetrexed 500 mg vial – Pemgem₹7,032.00₹3,408.64
Pertuzumab 420 mg injection – LUPIHER 2₹83,520.00₹37,358.35
Pertuzumab 420 mg injection – Womab₹74,992.50₹53,708.19

Source: PIB release dated 7 November 2026. These are selected examples, not a complete medicine list. Read the government price examples.

Different companies may market the same active ingredient under different brand names. Their earlier MRPs may also differ. Patients should compare the exact medicine, strength, dosage form and pack size. A price reduction for one brand should not be treated as a universal discount.

8. How to Check the Revised Medicine Price

Patients should use official price information before purchasing an affected medicine. The NPPA provides a revised-price section on its website.

Official price list: NPPA – Revised Prices of 137 Anti-Cancer Drugs.

  1. Open the NPPA revised-prices page.
  2. Find the latest dated anti-cancer medicine price list.
  3. Open the latest available document.
  4. Search for the medicine or brand name.
  5. Match the strength and dosage form.
  6. Check the pack size and manufacturer.
  7. Note the revised MRP.
  8. Compare it with the price printed on the medicine pack.

The NPPA page lists date-wise revised-price documents, including the 9 November 2026 list and earlier versions. The list may be updated as companies submit revised prices. For this reason, use the newest dated document available when checking a current purchase, and retain a copy or screenshot of the relevant entry with the bill.

What if the medicine pack shows a different price?

First confirm that you are comparing the same brand, strength, dosage form, pack size and manufacturer. Check the date of the NPPA document and whether a later revised list is available. Ask the pharmacy to explain the difference and request an itemised bill. If the discrepancy remains, keep the pack label, invoice and price-list entry and submit a complaint through the official channel. Do not rely only on a search-engine snippet or an old price screenshot.

9. What Should Patients Do at a Pharmacy or Hospital?

Patients and caregivers can take practical steps before making payment. A simple written check can prevent confusion, especially when the same generic medicine is sold under several brand names or in different strengths.

  1. Check the medicine pack: Read the printed MRP. Confirm the medicine name, strength and pack size.
  2. Compare the official revised price: Use the NPPA website or Pharma Sahi Daam. Confirm that the list matches the exact product.
  3. Ask for an itemised bill: Keep the pharmacy or hospital bill. It helps establish what the patient paid.
  4. Ask for clarification: If the charged price differs from the official MRP, ask the pharmacy to explain and correct the amount if required.
  5. Keep supporting documents: Save the medicine label, bill, prescription, payment proof and relevant price-list entry.

Patient safety reminder: Never stop, replace or reduce a prescribed cancer medicine without consulting the treating doctor. A lower-priced brand or formulation must still be clinically appropriate. Price information should support informed purchasing. It should not replace medical advice.

10. How to Report Overcharging

The government has stated that pharmacies and hospital pharmacies must not charge above the revised MRP for affected medicines. Consumers can report pricing-related complaints through official channels.

Pharma Jan Samadhan: Open the official consumer grievance portal.

NPPA Helpline: 1800-11-1255 (working days, 10:00 AM–6:00 PM).

A useful complaint should include the medicine’s generic and brand name, strength, dosage form, pack size, manufacturer, printed MRP, amount charged, pharmacy or hospital name, purchase date and a copy of the bill. Include a clear photograph of the label and the relevant NPPA price-list entry if available. Keep personal medical records private and share supporting documents only through official complaint channels.

The NPPA also lists its monitoring email as monitoring-nppa@gov.in. Its published helpline is 1800-11-1255 on working days, 10:00 AM to 6:00 PM. Check the NPPA website for the latest contact details before sending sensitive information.

11. Impact on Patients, Families and Healthcare

Relief for Families

Cancer treatment can place a significant financial burden on households. Some families use savings or borrow money to meet treatment costs. A lower medicine price can reduce part of this burden. The actual relief depends on the medicines used during treatment.

Better Price Transparency

Revised-price lists can help consumers compare prices. They also give pharmacies and hospitals a reference. Public price information can reduce confusion during medicine purchases.

Responsibility of Hospitals and Companies

Hospitals must ensure revised prices apply to relevant supplies from the implementation date. Pharmaceutical companies must report revised MRPs and communicate updated prices to retailers and hospitals. The government has also stated that companies cannot reduce production without permission. They must provide six months’ notice before completely discontinuing production of a medicine.

Importance of Monitoring

A price-control decision works only when the market follows it. Monitoring is needed across manufacturers, distributors, retailers and hospitals. State drug-control authorities also have a role in compliance. Patients need accessible complaint channels.

12. Important Limitations and Questions

Not Every Cancer Medicine Is Covered

The intervention identifies 137 non-scheduled anti-cancer drugs. It does not cover every medicine used in cancer treatment. Patients should check the official list.

Not Every Brand Has the Same Reduction

Different brands may have different earlier MRPs. Revised prices depend on the specific formulation and applicable calculation. A reported reduction for one brand should not be treated as a universal discount.

The Savings Figure Is an Estimate

The ₹3,540.38 crore figure represents estimated annual consumer savings. It is not an individual benefit amount or a direct government payment to patients.

Price Reduction Does Not Replace Medical Care

Medicine affordability is one part of cancer care. Patients may also need diagnostics, surgery, radiotherapy, hospital stays and follow-up treatment. The policy does not remove all these costs.

Supply Must Remain Reliable

A lower price has limited value if patients cannot obtain the prescribed medicine. Production, distribution and hospital supply must remain stable. The government’s supply-related requirements are therefore important.

13. Other Government Support That May Help Cancer Patients

The NPPA price intervention addresses the MRP of selected medicines. It is not the only public programme that may help with cancer-care expenses. Depending on eligibility, location, hospital empanelment, medicine availability and programme rules, patients may also explore the following government-supported options.

Ayushman Bharat – Pradhan Mantri Jan Arogya Yojana (AB-PMJAY)

AB-PMJAY provides eligible beneficiary families with cashless hospital care up to the scheme’s prescribed annual limit at empanelled hospitals. The government’s November 2026 backgrounder reports coverage of medical oncology, surgical oncology and radiation oncology procedures. Eligibility is not automatic for every household: check the beneficiary database, state-specific implementation and the hospital’s empanelment before admission. The scheme’s official portal is Ayushman Bharat PM-JAY.

Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP)

Jan Aushadhi Kendras supply quality-assured generic medicines at lower prices across multiple therapeutic categories. Availability of a particular anti-cancer medicine, strength or formulation is not guaranteed at every outlet. Patients should never substitute a prescribed cancer medicine on their own. Ask the treating oncologist or hospital pharmacist whether an appropriate equivalent is available and clinically suitable. Find scheme information through the official Jan Aushadhi portal.

AMRIT pharmacies

AMRIT (Affordable Medicines and Reliable Implants for Treatment) outlets aim to improve access to medicines and healthcare products for serious illnesses, including cancer. Prices, product range and stock vary by outlet. Patients can check current availability and price directly with an AMRIT pharmacy and compare it with the exact prescribed formulation.

Hospital social-work and patient-assistance desks

Government and charitable cancer hospitals may have medical social workers, patient-welfare desks or assistance programmes. Ask the hospital about eligibility for financial support, subsidised diagnostics, accommodation, travel assistance or manufacturer patient-assistance programmes. These are separate from the NPPA price cap and may have their own application criteria.

Important: These programmes have different eligibility and coverage rules. A scheme mention in this article does not guarantee that a specific patient, medicine or treatment bill will be covered.

14. What This Price Policy Does—and Does Not—Mean

It does meanIt does not mean
MRPs for identified formulations are revised under the NPPA intervention.Every cancer medicine in India has become cheaper.
The trade margin for the 137 identified non-scheduled anti-cancer drugs is capped at 30% of MRP under the order.Every patient receives a flat 30% discount.
Consumers can check the latest notified price and report suspected overcharging.The government will automatically refund every past purchase.
Retail and hospital pharmacies must follow the applicable revised MRP.The full cost of diagnosis, surgery, radiotherapy, hospitalisation and supportive care is capped by this order.
Price transparency can help patients and caregivers make informed purchase checks.Patients should change brands, doses or treatment plans without their oncologist.

The distinction is important. A medicine’s MRP is only one part of the total cost of cancer care. Treatment plans may include consultations, laboratory tests, imaging, day-care procedures, hospital admission, surgery, radiation, supportive medicines and follow-up. Patients should ask the treating hospital for a written estimate and discuss financial counselling where needed.

15. MASA World Editorial Insight & Community Guidance

Affordable healthcare is not only an economic issue. It is also a matter of dignity, access and public welfare.

The revised anti-cancer medicine prices are an important policy development. Their real value will depend on implementation. Patients need accurate prices at pharmacies and hospitals. They also need reliable medicine supplies and simple complaint channels.

MASA World recommends five practical actions:

  • Awareness: Help families understand the new medicine price rules.
  • Verification: Use the official NPPA list before accepting a medicine price.
  • Transparency: Encourage hospitals and pharmacies to display updated MRPs.
  • Patient protection: Keep bills and report suspected overcharging through official channels.
  • Community support: Help families access reliable information without making medical decisions for them.

NGOs, volunteers and public-interest organisations can support awareness campaigns. They should protect patient privacy and avoid making unsupported treatment claims.

Knowledge for Everyone. Opportunities for All.

16. Frequently Asked Questions

1. When did the revised cancer medicine prices take effect in India?

The revised MRPs took effect on 9 November 2026. The NPPA introduced the changes under its Trade Margin Rationalisation policy for selected anti-cancer medicines.

2. How many anti-cancer medicines are covered?

The policy identifies 137 non-scheduled anti-cancer drugs. The latest government announcement reports revised MRPs for 1,364 formulations.

3. How can I check the new price of my cancer medicine?

Visit the NPPA revised-price page or use the Pharma Sahi Daam application. Match the exact medicine, brand, strength and pack size.

4. Can a hospital or pharmacy charge more than the revised MRP?

The government says no chemist or hospital pharmacy can charge above the revised MRP for affected medicines. Keep the bill and report suspected overcharging through Pharma Jan Samadhan or the NPPA helpline.

5. Does the policy reduce the price of every cancer medicine?

No. It applies to 137 identified non-scheduled anti-cancer drugs. Patients must check whether their exact medicine and formulation appear in the official revised-price information.

6. Does the 30% trade-margin cap mean I will get a 30% discount?

No. The 30% figure is the maximum permissible trade margin under the order, not a flat discount promised to every patient. The actual MRP reduction differs by medicine and brand. Check the latest NPPA price list for the exact product.

7. Are patented cancer medicines included?

The government has stated that the 137 identified non-scheduled anti-cancer medicines include patented medicines. Coverage depends on the medicine being included in the notified list and applicable formulation details.

8. Are all strengths and dosage forms covered?

The order applies to the identified medicines and their listed versions, but the exact notified formulation and MRP must be checked. Do not assume that a price for one strength, vial size or pack automatically applies to another.

9. Can a hospital pharmacy charge a different amount?

The government says no chemist or hospital pharmacy may charge above the applicable revised MRP for covered medicines. Ask for an itemised bill and verify the exact pack and price-list entry. Other separately billed services or treatment charges are not the same as the medicine’s MRP.

10. Can I buy a cheaper brand instead of the one prescribed?

Do not switch a cancer medicine, brand, formulation or dose without discussing it with the treating oncologist. The doctor must confirm whether an alternative is clinically appropriate, including the active ingredient, strength, dosage form and treatment protocol.

11. Will the government refund the amount I paid before 9 November 2026?

The price announcement does not create an automatic refund for earlier purchases. If you believe a seller violated the applicable price rules, retain the bill and medicine details and seek guidance from NPPA through its official grievance channels.

12. Where can I find the latest official price list?

Use the NPPA Revised Prices of 137 Anti-Cancer Drugs page. Select the latest dated document and match the exact medicine and formulation.

17. Official References and Research Sources

  1. Department of Pharmaceuticals / PIB – Revised MRPs Effective 9 November 2026: latest reported formulations, consumer savings and price reductions.
  2. NPPA – Revised Prices of 137 Anti-Cancer Drugs: date-wise revised MRP documents.
  3. Department of Pharmaceuticals / PIB – Cheaper Cancer Medicines: What the New Margin Cap Means for Patients: policy background, trade-margin explanation, covered drug list and related support programmes.
  4. Ayushman Bharat – PM-JAY: official scheme information and beneficiary services.
  5. Pradhan Mantri Bhartiya Janaushadhi Pariyojana: official scheme information and Jan Aushadhi Kendra locator.
  6. Department of Pharmaceuticals / PIB – Trade Margin Rationalisation on 137 Anti-Cancer Drugs: policy scope and compliance requirements.
  7. Department of Pharmaceuticals / PIB – Revised Prices of Anti-Cancer Medicines: selected brand-level examples.
  8. NPPA – Circulars and Orders: revised MRP documents and official notices.
  9. Pharma Jan Samadhan: consumer grievance portal.

Editorial transparency: Research cutoff 10 November 2026. This article is based on official NPPA and Department of Pharmaceuticals / Press Information Bureau materials available by that date. Programme-wide savings are government estimates, not guaranteed individual savings. NPPA price lists may be updated as companies submit revised prices.

Health disclaimer: This article provides public-interest information. It does not replace medical advice. Patients should consult their treating doctor before changing medicines, brands or treatment plans.

Scroll to Top